12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

Concordia, Kadmon deal

Kadmon acquired salirasib ( KD032) from Concordia. The Ras antagonist is in Phase II testing to treat...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >